Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT With Lenalidomide Maintenance for Solitary Plasmacytoma
NCT06863584Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Feb 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in plasmacytoma, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Progression-Free Survival at 5 years. Started Feb 2025; status: recruiting.
02
Drugs
lenalidomide
03
Conditions
plasmacytoma
Beyond the preview
Go deeper on NCT06863584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06863584.